Funding for this research was provided by:
national institute for health research (nihr) leeds biomedical research centre (IS-BRC-1215-20015)
Received: 25 July 2021
Accepted: 3 January 2022
First Online: 18 January 2022
: Leeds West Research Ethics Committee (REC reference number 06/Q1205/169)Participants gave written informed consent to participate in the “CCP study”.Trial registration number: NCT02012764.
: Participants have given written informed consent for the publication of their anonymised data.
: Kulveer Mankia reports personal fees from Abbvie, UCB and Lilly, outside the submitted work. Paul Emery reports consultant fees from BMS, AbbVie, MSD, Lilly, Novartis, Pfizer, Roche, and Samsung outside the submitted work. He also reports research grants from AbbVie, BMS and Lilly, outside the submitted work. Leticia Garcia-Montoya, Jacqueline L.Nam, Laurence Duquenne, Catalina Villota-Eraso, Andrea Di Matteo and Collette Hartley have no disclosures.